Treatment Challenges Persist for Complicated Staphylococcus aureus Infections, Especially MRSA

For MRSA bacteremia, treatment has long relied on established antibiotics, most notably vancomycin. In use since the 1950s, vancomycin remains a cornerstone therapy due to its sustained effectiveness and the rarity of resistance in S aureus. However, its use is far from straightforward. Clinicians must carefully manage dosing through therapeutic drug monitoring, and the drug carries a risk of nephrotoxicity, complicating treatment in vulnerable patients.

An alternative option, daptomycin, offers some advantages, including simpler once-daily dosing and comparable efficacy to vancomycin in clinical trials. Yet it is not without limitations. Daptomycin cannot be used for pneumonia due to inactivation in the lungs, and more concerningly, resistance can emerge during treatment. Clinical studies have documented cases where patients who failed therapy developed resistant strains, raising concerns about its long-term reliability.

Together, these challenges underscore a central issue in MRSA management: while current therapies can be effective, they are often limited by toxicity, logistical complexity, or the potential for resistance. As a result, there remains a critical need for newer therapies that are both easier to administer and more resilient against resistance, particularly for patients with severe or complicated infections.

Disclaimer: Holland was the Chair of Adjudication for the ERADICATE trial.

This video series has been produced independently by Contagion Live and supported through a educational grant by Innoviva Specialty Therapeutics inc